For the quarter ending 2025-09-30, ATXS made $706K in revenue. -$31,643K in net income. Net profit margin of -4482.01%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 706 | - | ||
| Research and development | 24,149 | 25,945 | ||
| General and administrative | 10,661 | 9,875 | ||
| Total operating expenses | 34,810 | 35,820 | ||
| Loss from operations | -34,104 | -35,820 | ||
| Interest and investment income | 2,498 | 2,889 | ||
| Other expense, net | -37 | -121 | ||
| Total other income, net | 2,461 | 2,768 | ||
| Net loss | -31,643 | -33,052 | ||
| Earnings per share, basic | -0.55 | -0.57 | ||
| Earnings per share, diluted | -0.55 | -0.57 | ||
| Weighted average number of shares outstanding, basic | 58,005,928 | 58,005,312 | ||
| Weighted average number of shares outstanding, diluted | 58,005,928 | 58,005,312 | ||
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)